Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

Emma M. Kileel,Carlos D. Malvestutto,Janet Lo,Kathleen Fitch,Carl J. Fichtenbaum,Judith A. Aberg,Markella Zanni,Esteban Martinez,Nwora Lance Okeke,Princy Kumar,Esau Joao,Sara H. Bares, Daniel Berrner,Marek Smieja, Jhoanna C. Roa,Sara McCallum,Pamela S. Douglas,Heather J. Ribaudo,Steven K. Grinspoon

CLINICAL INFECTIOUS DISEASES（2023）

引用 0|浏览35

暂无评分

摘要

Over 2-years of follow-up, integrase strand transfer inhibitor (INSTI)-use was associated with weight gain among those on an INSTI <2 years at entry (+0.27 kg/m(2)/year; 95% confidence interval [CI], .22 to .33 vs +0.17 kg/m(2)/year; 95% CI, .12 to .23; P = .01), but not those on an entry INSTI >2 years.

查看译文

关键词

integrase strand transfer inhibitors (INSTIs), weight, body mass index (BMI), HIV

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要